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In this issue of 
 
Value in Health
 
, Delea and col-
leagues report the results of a well-conducted ret-
rospective database analysis investigating the costs
and incidence of 5-FU toxicity among metastatic
colorectal cancer patients [1]. The primary finding
in this study was that patients treated with 5-FU
undergo frequent hospitalization due to toxicity
associated with chemotherapy compared with pa-
tients who have not received chemotherapy. The
cost of hospitalizations due to toxicity at 10.5
months was $2716 higher for 5-FU patients than
for those with no 5-FU treatment. These findings
are significant in that colorectal cancer is common
and approximately one-half of patients with meta-
static colorectal cancer receive 5-FU treatment.
As a health outcomes researcher, I understand
firsthand the difficulty and subtlety associated with
conducting such an analysis. Many methodological
issues need to be accounted for and tackled by the
research team to preserve internal validity. Exam-
ples of such issues include, but are certainly not
limited to, integration of many different claim sub-
types in the Medicare system, estimation of the
date of 5-FU treatment based on outpatient claims,
and determination of the expected cost of hospital-
ization, which is conditional on the probability of
survival to a given time interval.
As a health outcomes researcher in a prominent
health-care system, I also understand the level of
skepticism the average clinician holds for cost
studies. The disconnect between health outcomes
researchers and clinical decision makers became
apparent immediately after I began my current ten-
ure. I recently heard a clinician/researcher remark
that “outcomes research is more about the meth-
ods than the results.” The meaning of his com-
ment, of course, is that sometimes the struggle to
maintain internal validity is so fierce that external
validity is sacrificed, or worse yet, the research
question that is important to these clinicians on the
“front line” is never even asked. We as outcomes
researchers need to understand that feelings like
these are pervasive among highly educated and ex-
perienced clinicians and researchers who are mak-
ing treatment and formulary decisions.
For outcomes research to be optimally useful for
institutional decision makers, patient outcomes and
total cost of care need to be examined. With this in
mind, I tried to envision how the Delea study would
be received at my institution. The Pharmacy and
Therapeutics (P&T) Committee would ask for my
opinion on the methods. I would report that this
study was very well done for what it attempted to
do. The conversation would then turn to the specific
findings: Patients treated with 5-FU had higher costs
and incidence of hospitalization for adverse effects;
however, they also survived longer. This improved
survival would be a major finding for institutional
decision makers but seems to be largely ignored in
this study. As the discussion turned to cost, few cli-
nicians would be surprised that 5-FU patients fre-
quently suffered from toxicity with high associated
costs. However, it is possible that those not treated
with 5-FU experienced greater costs associated with
cancer relapse and mortality. The burning issue
from the institutional perspective would center on
the total cost of care for these treatment groups—
something the Delea study was not designed to de-
termine. These bottom-line oriented results would
be particularly interesting to financial officers, who
have the unenviable task of keeping health systems
afloat fiscally. Another important end point that
could not be measured in this analysis, but would be
important for a P&T committee to consider, is pa-
tient preference. It would be very enlightening to
know whether the increased risk of side effects
would be outweighed by a better chance of survival
from the patient’s perspective.
In the end, this study, while well done, leaves im-
portant issues from the health-care-system perspec-
tive unresolved. We in the outcomes research com-
munity would do well to understand the motives
and rationale of our health-care-system colleagues.
The right questions should be asked to give formu-
lary decision makers the bottom-line data they need.
We should recognize that the clinician’s highest goal
is the health and survival of patients. Whenever ad-
ditional cost is juxtaposed with greater survival, the
bar is raised very high for the outcomes researcher.
The next logical question that needs to be answered
is, Is the additional cost worth the additional sur-
vival? This is the question that the P&T committee
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needs answered. The results from our studies need
to be as important as the methods.—Kenneth M.
Shermock, PharmD, IH Page Center for Health
Outcomes Research, The Cleveland Clinic Founda-
tion, Cleveland, OH.
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